Clinical Trial Update: Liposomal Bupivacaine With or Without Hydromorphone for the Improvement of Pain Control After Laparotomy in Patients With Gynecological Malignancies [Phase 4]

View source ↗

Summary

A Phase 4 trial assessed whether liposomal bupivacaine, with or without hydromorphone, improves postoperative pain control after laparotomy in patients with gyn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecologic Cancer

Drugs mentioned

• Hydromorphone (hydromorphone)
• Liposomal bupivacaine (bupivacaine liposome injectable suspension)

Snippet

Sponsor: Mayo Clinic | Conditions: Malignant Female Reproductive System Neoplasm | Phase 4 | Status: COMPLETED | Results posted: 2024-10-16